GLP-1 for type 2 diabetes.

Your doctor mentioned a GLP-1 for your diabetes. If you have spent the last few years hearing about these drugs as weight-loss medications, that framing can feel jarring. The GLP-1 class actually started in diabetes care. Liraglutide, the first member to reach the US market, was approved for type 2 diabetes in January 2010, nearly five years before its higher-dose cousin Saxenda was approved for weight management. Every newer member followed the same path: diabetes label first, weight-management label later (or sometimes never).

This article is for the person whose HbA1c has stayed above goal on metformin, or who is already on Ozempic or Mounjaro and wants to understand the trial evidence behind the prescription. It is also for the person on Wegovy or Zepbound for weight who has discovered they also have type 2 diabetes and wants to know how the same molecule plays in a diabetes context. Everything below describes what the trials show and what the FDA labels say. None of it is a recommendation to start, stop, switch, or change the dose of any medication. Those decisions live with your prescriber.

What a GLP-1 actually does for blood glucose.

GLP-1 (glucagon-like peptide-1) is a gut-derived hormone the body releases after a meal. GLP-1 receptor agonists and the dual GIP/GLP-1 agonist tirzepatide act through four mechanisms relevant to glycemia: they amplify insulin secretion from pancreatic beta cells when blood glucose is elevated (then back off when glucose returns to normal); they suppress glucagon release from alpha cells in the same glucose-dependent way; they slow gastric emptying, blunting the postprandial glucose spike; and they act on hypothalamic appetite centers, reducing food intake and contributing to weight loss that itself improves insulin sensitivity.

The glucose-dependent feature is why hypoglycemia is uncommon with GLP-1 monotherapy: when blood sugar is low, the insulin-stimulating effect effectively switches off. Sulfonylureas like glipizide push insulin regardless of glucose level. Combined with a sulfonylurea or with insulin, a GLP-1 loses its glucose gate, and hypoglycemia risk rises. The ADA Standards of Care and FDA labels both recommend reducing the sulfonylurea or insulin dose when starting a GLP-1.

GLP-1's effect on insulin secretion is glucose-dependent. When blood sugar is low, the effect turns off, which is why hypoglycemia is uncommon with these drugs unless they are combined with a sulfonylurea or insulin.

The FDA-approved options for type 2 diabetes.

Five branded GLP-1 receptor agonists are FDA-approved for type 2 diabetes glycemic control, plus the first generic liraglutide (approved December 2024). The single-active-ingredient versions designed for weight management, including Wegovy, Zepbound, and Saxenda, are not labeled for type 2 diabetes even when they share a molecule with a diabetes-labeled product.

Two practical notes the table cannot show. The same active ingredient under a different brand is not interchangeable at the pharmacy counter. And the indication on the prescription drives what insurance pays for: Ozempic with ICD-10 E11.x (type 2 diabetes) flows through a different coverage pathway than Wegovy with E66.x (obesity), even though the molecule is identical.

Where the ADA puts GLP-1s in the algorithm.

The 2025 ADA Standards of Care, Section 9, groups injectable semaglutide and tirzepatide together as the highest-efficacy options for combined glycemic and weight outcomes in type 2 diabetes. Dulaglutide and liraglutide are listed as high-efficacy. The ADA does not designate one molecule as preferred over another. Metformin remains the typical first-line agent, and a GLP-1 is usually added to metformin rather than replacing it.

A more interesting line in the 2025 guidelines: in adults with type 2 diabetes without evidence of insulin deficiency, a GLP-1 receptor agonist or GIP/GLP-1 dual agonist is preferred over starting insulin. The 2026 update extended the cardiorenal framing. A GLP-1 with demonstrated cardiovascular benefit is now recommended in adults with type 2 diabetes plus established ASCVD, plus the same in adults with obesity plus symptomatic HFpEF for heart-failure event reduction, and in adults with type 2 diabetes plus advanced chronic kidney disease.

What the glycemic trials show.

The most-cited head-to-head in type 2 diabetes is SURPASS-2. It randomized 1,879 adults on background metformin to once-weekly tirzepatide (5, 10, or 15 mg) or once-weekly semaglutide 1 mg for 40 weeks. Mean HbA1c reduction was 1.86% on semaglutide 1 mg, 2.01% on tirzepatide 5 mg, 2.24% on tirzepatide 10 mg, and 2.30% on tirzepatide 15 mg. All three tirzepatide doses were statistically superior to semaglutide 1 mg, though absolute differences are small for many patients. The composite endpoint (HbA1c at or below 6.5% plus at least 10% body weight loss plus no severe hypoglycemia) was reached by 60% on tirzepatide 15 mg vs 22% on semaglutide 1 mg.

Other glycemic trials sketch the landscape. SUSTAIN FORTE supported Ozempic 2 mg (about 2.1% HbA1c reduction, 89% below 7%). AWARD-11 established the higher 3.0 mg and 4.5 mg Trulicity doses. PIONEER supported oral semaglutide at 7 and 14 mg, with 69% and 77% of participants reaching HbA1c at or below 7% vs 31% on placebo. Liraglutide 1.8 mg in LEAD reduced HbA1c by roughly 1.0 to 1.5%.

Heart and kidney trials behind the indications.

GLP-1s are the only class of type 2 diabetes drugs, alongside SGLT2 inhibitors, with multiple completed cardiovascular outcome trials. The headline trials are LEADER, SUSTAIN-6, PIONEER 6, REWIND, FLOW, and the most recent entry, SURPASS-CVOT.

LEADER (NEJM 2016) studied liraglutide in 9,340 adults at high cardiovascular risk and produced a MACE hazard ratio of about 0.87. SUSTAIN-6 (NEJM 2016) studied subcutaneous semaglutide in 3,297 adults over 104 weeks; the composite of cardiovascular death, nonfatal MI, and nonfatal stroke was 6.6% on semaglutide vs 8.9% on placebo (HR 0.74, 95% CI 0.58 to 0.95). REWIND (Lancet 2019) studied dulaglutide in 9,901 adults over 5.4 years and found a 12% relative MACE reduction (HR 0.88).

PIONEER 6 (NEJM 2019) was the original cardiovascular outcomes trial for oral semaglutide and met non-inferiority for MACE (HR 0.79). The larger SOUL trial then read out and on October 17, 2025 the FDA approved Rybelsus for cardiovascular risk reduction in adults with type 2 diabetes and either established cardiovascular disease or chronic kidney disease. SOUL showed a 14% relative MACE reduction at four years on oral semaglutide 14 mg vs placebo, making Rybelsus the first oral GLP-1 with a cardiovascular risk reduction indication.

FLOW and the first kidney indication.

FLOW was the first dedicated kidney outcomes trial of a GLP-1 receptor agonist. It showed a 24% relative reduction in major kidney and cardiorenal endpoints in adults with type 2 diabetes and chronic kidney disease, and prompted the FDA to add a kidney indication to Ozempic's label on January 28, 2025.

FLOW (NEJM 2024) was the first dedicated kidney outcomes trial in this class. It randomized 3,533 adults with type 2 diabetes and chronic kidney disease, all on a renin-angiotensin system inhibitor, to semaglutide 1 mg per week or placebo. The composite primary endpoint (major kidney events plus cardiovascular death plus kidney death) showed a 24% relative risk reduction (HR 0.76). Pre-specified secondary endpoints were also positive: eGFR slope improved by 1.16 mL/min/1.73m² per year, MACE fell 18%, and all-cause mortality fell 20%.

SURPASS-CVOT and what it did and did not show.

SURPASS-CVOT (NEJM December 2025) was the first completed cardiovascular outcomes trial for tirzepatide. It randomized 13,165 adults with type 2 diabetes and established ASCVD to tirzepatide or dulaglutide, with a median four-year follow-up. Tirzepatide met the non-inferiority bar for three-point MACE versus dulaglutide (12.2% vs 13.1%), with a numerical 8% relative reduction, plus a 16% reduction in all-cause mortality and superior metabolic and renal benefits in pre-specified secondary endpoints.

The honest framing: SURPASS-CVOT is a positive non-inferiority trial. It did not formally meet superiority for the primary MACE endpoint. The mortality and secondary-endpoint signals are clinically relevant, but characterizing tirzepatide as cardiovascularly superior to dulaglutide on the basis of MACE is not what the primary analysis supports. The practical takeaway is that tirzepatide is now backed by a completed cardiovascular outcomes trial alongside semaglutide, dulaglutide, and liraglutide.

How "GLP-1 for T2D" differs from "GLP-1 for weight".

Ozempic and Wegovy are both semaglutide. Mounjaro and Zepbound are both tirzepatide. The active ingredient is identical inside each pair. What differs is the FDA-approved indication, the dose ceiling, the titration schedule, and what your insurance is willing to pay for.

Ozempic is labeled for type 2 diabetes glycemic control, plus cardiovascular risk reduction in type 2 diabetes plus ASCVD, plus reduction of kidney disease progression in type 2 diabetes plus CKD (January 2025). It tops out at 1 mg or 2 mg per week. Wegovy is labeled for chronic weight management and for MACE reduction in cardiovascular disease with overweight or obesity (March 2024), with a target maintenance dose of 2.4 mg per week on a more aggressive titration. Mounjaro and Zepbound share the same 2.5 to 15 mg titration; the dose ceiling does not differ, but the labeled indication and insurance pathway do.

Off-label crossover happens. A patient with both type 2 diabetes and a BMI of 34 may be prescribed Wegovy by an obesity-medicine clinician, or Ozempic by an endocrinologist. Which prescription gets covered is a decision for the prescriber and pharmacist working with the patient's specific formulary. We describe the landscape. We do not recommend pursuing one prescription over another for any individual reader.

Ozempic and Wegovy share an active ingredient. The label, the dose ceiling, and what insurance is willing to pay for are what is different. The pharmacy will not substitute one for the other.

Side effects in a type 2 diabetes context.

The side-effect profile in type 2 diabetes trials is broadly similar to the weight-management trials of the same molecule. Nausea, diarrhea, constipation, and vomiting are the most common adverse events, most prominent during dose escalation and improving with time. Frequency and severity are dose-dependent, which is why titration schedules are deliberately slow. The side-effects timeline mirrors weight-management trials, though severity is often lower at type 2 diabetes dose ceilings. Fatigue during titration is reported by a meaningful minority of patients.

Two type 2 diabetes-specific points deserve attention. The first is the hypoglycemia interaction. GLP-1 monotherapy has hypoglycemia rates at or below 2% in trials. Combined with a sulfonylurea (glipizide, glyburide, glimepiride) the risk rises substantially, because sulfonylureas uncouple the glucose-dependence that normally protects against hypoglycemia. The same logic applies with prandial insulin. The size of any dose reduction when initiating a GLP-1 is individualized and belongs to the prescriber.

The second is the retinopathy signal from SUSTAIN-6. In the original cardiovascular outcomes trial of subcutaneous semaglutide, the rate of diabetic retinopathy complications (vitreous hemorrhage, blindness, or conditions requiring photocoagulation or intravitreous treatment) was higher on semaglutide than on placebo: 3.0% vs 1.8%, hazard ratio 1.76 (95% CI 1.11 to 2.78). The leading explanation is that a rapid drop in HbA1c can transiently worsen pre-existing severe retinopathy, a phenomenon seen previously with intensified insulin therapy. The FLOW trial in type 2 diabetes plus CKD did not replicate the magnitude of this signal. If you have a known history of severe diabetic retinopathy, the prescriber will likely weigh the SUSTAIN-6 finding and may want a recent ophthalmology assessment before starting or escalating a GLP-1.

Acute pancreatitis remains a class warning, with pooled rates of roughly 0.1 to 0.2% per year in CVOTs and no statistically significant difference from placebo. Gallbladder events are modestly increased across the class, more relevant in the higher-dose weight-management setting than at the type 2 diabetes dose ceilings.

How GLP-1 fits with other type 2 diabetes medications.

Metformin remains the typical first-line agent unless contraindicated, and a GLP-1 is most often added to metformin rather than replacing it. SURPASS-2 and most other GLP-1 trials in type 2 diabetes assumed background metformin. GLP-1 plus basal insulin is common when glycemic targets are not met; the ADA prefers GLP-1 over prandial insulin in adults without evidence of insulin deficiency, and basal insulin titration usually needs to be adjusted downward when a GLP-1 is added.

GLP-1 plus an SGLT2 inhibitor is the emerging "four-pillar" combination for type 2 diabetes patients with high cardiorenal risk: GLP-1 receptor agonists primarily reduce atherosclerotic events and weight, SGLT2 inhibitors primarily reduce heart failure events and slow CKD progression. The ADA's 2026 update endorses both classes when each is independently indicated. GLP-1 plus DPP-4 inhibitor is not recommended (same pathway, no additive benefit). GLP-1 plus sulfonylurea is possible but requires the sulfonylurea dose reduction noted above.

Who should not take a GLP-1 receptor agonist.

The FDA labels for the entire class carry a boxed warning against use in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2), based on a rodent thyroid C-cell tumor signal. Pregnancy is a strong caution: animal data show fetal harm, and patients of childbearing potential are advised to discontinue at least two months before a planned pregnancy. Severe gastroparesis is a contraindication on the Ozempic label, because the class slows gastric emptying.

Type 1 diabetes is off-label for all five branded GLP-1s; none is a substitute for insulin in type 1. A personal history of acute pancreatitis is a class warning that calls for clinical judgment. Pediatric type 2 diabetes use varies: Trulicity, Victoza, and Mounjaro are approved for ages 10 and up; Ozempic remains adult-only as of mid-2026.

What to bring to the conversation with your prescriber.

The decision of which GLP-1 fits your situation is one your prescriber makes with you, weighing your HbA1c trajectory, your cardiovascular and kidney history, your other medications, your insulin resistance and weight goals, and what your insurance plan will cover. Questions that tend to be useful in that visit include:

• Which GLP-1 does my insurance currently cover for type 2 diabetes glycemic control, and what does the copay look like at the maintenance dose?
• Do I have established cardiovascular disease or chronic kidney disease, and does that change which molecule is preferred for me?
• If I am on a sulfonylurea or insulin, what is the plan for dose adjustment when I start the GLP-1?
• Do I have a history of diabetic retinopathy that requires an ophthalmology check before starting?
• What does the titration schedule look like, and how will we handle GI side effects if they appear?
• What is the plan if I have to stop the medication, and how does my prescriber think about HbA1c rebound after stopping?

None of these has a single correct answer. The point of asking them is to make the trade-offs explicit before the prescription gets written. The trial evidence supports the GLP-1 class as a foundational option for type 2 diabetes glycemic control with substantial cardiovascular and (in the FLOW population) renal benefit. Which agent, at what dose, in what combination, and for how long is a clinical decision, not a consumer one.

This article is for educational purposes only and is not medical advice. It does not recommend any specific medication, dose, or treatment plan. Decisions about which GLP-1, if any, fits your situation belong with your prescriber. Read more about our editorial process and our terms.